Preliminary results with a long-acting progestational preparation. (Abstract only)

Author: 
Heeres SG
Source: 
In: Wood, C. and Walters, W.A., eds. Fifth World Congress of Gynaecology and Obstetrics, Sydney, September 1967. New York Appleton-Century-Crofts, 1967. p. 348
Abstract: 

In recent years a great number of synthetic drugs with progestational activity have been introduced for clinical use, either alone or in combination with estrogenic substances. The author studied the ovulation-inhibiting properties of a new progestational compound (20beta-hydroxy-4-19-nor-pregnene-3-one, 20beta phenylpropionate = Xinogestone, Organon, Holland) in a small number of patients. In the pharmacological studies hitherto performed the compound was highly active in all tests, which were used for the assessment of progestational effects (Clauberg test, Deciduoma test, test of symphyseal relaxation in spayed guinea pigs). It also maintained pregnancy in spayed rats. No masculinization or other abnormalities were observed in the offspring of mother rats, which had been treated with Xinogestone. The same holds for the offspring of mother rabbits treated with this compound. The steroid appeared to be a potent antifertility agent with prolonged activity. In the rat, it inhibited ovulation and, depending on the dose, suppressed estrus for a more or less extended period. For clinical practice Xinogestone holds promise as a long-acting progestational preparation, and because of its strong antifertility properties, trials in this field seem especially worthwhile. The present communication is a preliminary report on women known to be regularly ovulating and with regular menstrual cycles who were injected with 100 mg of the compound on Day 5 of the cycle. In a so-called ABA trial (A, control cycle; B, the cycle in which the compound was injected), basal body temperature was determined throughout the whole period of 3 cycles. Pregnandiol excretion values, vaginal smears, and endometrial biopsy were checked on Days 8 and 23 of the control and treatment cycle. The time and duration of bleeding, the frequency of spotting and breakthrough bleeding and tolerance to the preparation were studied.(FULL TEXT)

Language: 
Year: 
Document Number: 
670662
Add to my documents. Add to My Documents